WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study - Wikidata - awgldk - TriplyDB

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study

http://www.wikidata.org/entity/Q33438898

about

Management of trypanosomiasis and leishmaniasis Identification of the molecular attributes required for aminoglycoside activity against Leishmania Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Drug discovery algorithm for cutaneous leishmaniasis.Parasite load decrease during application of a safe and easily applied antileishmanial aminoglycoside cream.Early curative applications of the aminoglycoside WR279396 on an experimental Leishmania major-loaded cutaneous site do not impair the acquisition of immunity.Easy identification of leishmania species by mass spectrometry New trends in aminoglycosides use.Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis.Structures, targets and recent approaches in anti-leishmanial drug discovery and development.Leishmanicidal Activity of Films Containing Paromomycin and Gentamicin Sulfate both In Vitro and In Vivo Leishmaniasis in the United States: treatment in 2012 Spatio-temporal Genetic Structuring of Leishmania major in Tunisia by Microsatellite Analysis.Old World cutaneous leishmaniasis: diagnosis and treatment Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment.Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis.Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management.Drug delivery systems for the topical treatment of cutaneous leishmaniasis.Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.Synthesis and antileishmanial evaluation of some 2,3-disubstituted-4(3H)-quinazolinone derivatives Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.Travelers with cutaneous leishmaniasis cured without systemic therapy.Interventions for Old World cutaneous leishmaniasis.Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs.

P2860

Q24596889-79CC2229-D4E1-46F8-864A-0CC5809B1DC1 Q27679272-2328AEE7-95E5-42A2-B876-D915E136D90D Q30275257-B75C14AE-5DF8-46FE-BB8D-5FB886B3561C Q30414859-59D6E334-D5EC-4CE6-A80D-B118EC37878D Q33650039-1E456E46-71A7-4FFD-B97E-494A4A5A7EE3 Q33676413-A6EA262E-044B-463C-B61D-49AD31625252 Q33716734-31895FD7-1A76-4BE4-9B57-D070862873AD Q33951177-1311DBFD-4767-4404-8FC3-212A9121B3A5 Q34515998-207AC099-CD21-4BC6-BB25-00AF157E0BDE Q34654206-35947A68-B648-4AC4-8AC6-077427FC1909 Q35012968-0A2A0FBC-E1BA-4A0C-840D-C2282E749C0A Q35758135-33CC1F9C-D14A-49CB-86AF-47219D646380 Q35771790-2FA7EF56-5DE7-4D3E-88AE-C965A156DA17 Q35991151-C3C1B7ED-A241-4704-9E1A-159D09381C22 Q37010084-E76BE5D4-7B99-429F-A8E3-4BCC5ABDE988 Q37089640-563E7AD5-FF6C-402B-98FE-129AE6656764 Q37166175-CC7D01F9-FE8D-44D3-9A7F-44260D3D323F Q37475900-9D436324-89AC-4A14-A316-2E884232AB4D Q37693923-D7A58E9C-3B46-41ED-9BB1-671BEABD11E3 Q38020882-82D56236-7FB1-4D9F-AAA6-061FF5AFE75C Q38136837-C414FCD2-1C56-4C63-BCA9-D078147C5077 Q38156421-1AF0C8E1-71AF-4FC9-B03C-66A03F8139A7 Q38205451-2A5107FD-70F3-4DC8-B0C9-CE76F3375004 Q38263615-CB1457D9-AFFD-49DC-9D95-F57C6C6D6BB1 Q38511211-EBD17850-35A9-44B5-A8C6-F8CE334B9ED9 Q38909747-5785E772-56FE-4B9D-BAB9-A8740B09954C Q39256533-F5C09722-330E-4DC8-B12C-DDC6A52828CA Q41677439-F46DCF30-859F-4BEC-9FC1-8278104EB108 Q45802306-82FB0716-179E-40A4-A457-F987F7CC8364 Q46250558-540C3CB3-0C9D-495A-985F-EF3D66C112E3 Q46258168-9D4111B0-DEAD-4AD0-BFFE-3FE39F63E886 Q50042596-FCA07194-C449-4B25-8EB6-E0B84255F54A Q53522202-51597EC2-4033-46D8-B1B2-D7A9F9AFB18E

P2860

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study

http://www.wikidata.org/entity/Q33438898

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

WR279,396, a third generation ...... lind, placebo controlled study

@ast

WR279,396, a third generation ...... lind, placebo controlled study

@en

type

label

WR279,396, a third generation ...... lind, placebo controlled study

@ast

WR279,396, a third generation ...... lind, placebo controlled study

@en

prefLabel

WR279,396, a third generation ...... lind, placebo controlled study

@ast

WR279,396, a third generation ...... lind, placebo controlled study

@en

P1433

Q33438898-B9B2EF6C-731A-40E5-B244-7BE3F3356BFF

P1476

Q33438898-27FFA783-A648-4F1B-A249-DCA344A100E4

P2093

Q33438898-04EFC25D-EE99-4363-9731-A38B73B8FC4C

Q33438898-3095DC40-0400-4359-8DF6-6A9DA0D6B8F7

Q33438898-3D9E9BB2-547A-443C-B730-D8DFAA32221D

Q33438898-48F67FB6-34E3-49F5-8AF3-2B98F7C9C5CE

Q33438898-5751D361-6070-4D6A-AF8D-DB790D72E68E

Q33438898-856765C0-7F75-4040-8B8B-4995CDD3146F

Q33438898-AE5FD6BA-75EF-4EEB-9674-D0B038AAADE0

Q33438898-BC279BDA-3C01-42FF-83BB-0EFD752B1BCE

Q33438898-D08A6E4D-7677-450E-9DE2-97901C52D072

Q33438898-E526E318-D5D4-41E0-B1CD-4CFD2C0E0356

P2860

Q33438898-0070BA6F-6803-474D-A67B-CFC4A79F91BE

Q33438898-035289D1-C407-4DF7-A90E-B143DBE8FEEE

Q33438898-03C1D23D-03E9-4087-8CB6-9F93172BEDC1

Q33438898-1293A58C-F593-4338-AEC6-713D8139EFDD

Q33438898-15EC64B9-4FE6-40ED-9FEA-523D01996644

Q33438898-17C1814B-6938-4DCA-AE5D-549187D0B64A

Q33438898-1BD01C32-3FF1-4A95-8480-96116B416469

Q33438898-3C23C92C-4416-4D50-8691-91887D7C2F42

Q33438898-4A21F86D-2BD0-4E01-AB0C-E4EFB1A43CCA

Q33438898-5067DA88-149A-4B34-89B1-2E4E46AE6D3A

P304

Q33438898-FCB73F06-EDED-40EF-A7EF-A5DB3077F7FA

P31

Q33438898-E20EB831-9485-4195-B86B-B2A5E991DBF5

P356

Q33438898-C7634538-E902-4F75-8410-B3789502DFE0

P407

Q33438898-CB60597A-251A-4A75-9141-82C9C9289ED6

P433

Q33438898-C943BF23-DB25-49B2-B969-31F1EC88B714

P478

Q33438898-9617A3E9-6B43-413F-8402-619278193689

P50

Q33438898-95754A61-28B3-45A4-8C76-6EB73261E0E7

Q33438898-A9486543-4FB4-4BC5-8D46-96F9625DFAF8

P577

Q33438898-EF2067E8-E91A-44E3-A2EF-48BB87EF6771

P5875

Q33438898-3397D213-1C81-48F5-AB8C-1A19415EBB02

P698

Q33438898-9A844CE1-6C92-42EA-9621-FDECE63EF0CC

P921

Q33438898-2E13AEE4-34FF-4531-886B-9AAEF8AA1DA5

Q33438898-F585AA9A-D274-41F7-94C2-D48C8F9EB71C

P932

Q33438898-F0D8A9AD-8AAA-484A-8482-E6891A459154

P356

JOURNAL.PNTD.0000432

P1433

PLOS Neglected Tropical Diseases

P1476

WR279,396, a third generation ...... lind, placebo controlled study

@en

P2093

Afif Ben Salah

http://www.w3.org/2001/XMLSchema#string

Amor Zâatour

http://www.w3.org/2001/XMLSchema#string

Gloria Morizot

http://www.w3.org/2001/XMLSchema#string

Matthew T Downs

http://www.w3.org/2001/XMLSchema#string

Max Grögl

http://www.w3.org/2001/XMLSchema#string

Nabil Bel Haj Hamida

http://www.w3.org/2001/XMLSchema#string

Nathalie Ben Massoud

http://www.w3.org/2001/XMLSchema#string

Nissaf Ben Alaya

http://www.w3.org/2001/XMLSchema#string

Philip L Smith

http://www.w3.org/2001/XMLSchema#string

Zaher El Ahmadi

http://www.w3.org/2001/XMLSchema#string

P2860

Drug development for neglected diseases: a deficient market and a public-health policy failure

Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

Epidemiology of the leishmaniases.

Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.

Injectable paromomycin for Visceral leishmaniasis in India.

Topical treatment for cutaneous leishmaniasis.

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.

Current treatment approaches to leishmaniasis.

Treatment of cutaneous leishmaniasis among travellers.

P304

e432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PNTD.0000432

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Koussay Dellagi

P577

2009-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24401430

http://www.w3.org/2001/XMLSchema#string

P698

19415122

http://www.w3.org/2001/XMLSchema#string

P921

P932

2673687

http://www.w3.org/2001/XMLSchema#string